Allogeneic Cardiosphere-derived Cells for the Treatment of Heart Failure with Reduced Ejection Fraction: Results of the Dilated cardiomYopathy iNtervention with Allogeneic Myocardially-regeneratIve Cells (DYNAMIC) trial.
The DYNAMIC trial assessed the safety and explored the efficacy of multivessel intracoronary infusion of allogeneic cardiosphere-derived cells (CDCs) in patients with heart failure and reduced ejection fraction (HFrEF). We enrolled 14 patients with EF≤35% and NYHA III-IV despite maximal medical- and device-based therapy in this single-center, open-label trial. Intracoronary catheterization delivered four escalating doses (totaling 37.5-75 million cells) by sequential non-occlusive technique to all three major coronary arteries. The primary safety endpoint was a composite of post-infusion TIMI flow, ventricular tachycardia/fibrillation, sudden death, major adverse cardiac events or acute myocarditis within 72 hours. Twelve patients were male and EF averaged 23.0% (±4.5%). No primary safety endpoints were observed. Two patients died of HFrEF progression 9- and 12-months following infusion. Compared to baseline, there was an improvement in EF (26.8% vs. 22.9%, p=0.023) and left ventricular end-systolic volume (139.5 vs. 177.8, p=0.03) at 6 months. Quality of life (QoL) scores and NYHA class (p=0.006) improved at 6 months. At 12 months, the improvement in EF and QoL remained significant. Global intracoronary infusion of allogeneic CDCs is safe and feasible. The efficacy of allogeneic CDCs in HFrEF needs to be tested in larger randomized trials.